Regeneron and Sanofi Receive Complete Response Letter from FDA for Sarilumab an …

Sanofi and Regeneron remain committed to the development of sarilumab and providing the therapy to RA patients in the U.S. as quickly as possible. IfRead more...
Read the full story: Bioportfolio Latest News